UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 454

Sortiert nach

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Leukemia, 2017-06, Vol.31 (6), p.1340-1347

2017

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Leukemia, 2014-11, Vol.28 (11), p.2188-2196

2014

Link zum Volltext

Verfügbarkeit prüfen

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

Haematologica (Roma), 2015-12, Vol.100 (12), p.1495-1507

Wiestner, Adrian

2015

Link zum Volltext

Verfügbarkeit prüfen

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Leukemia, 2014-10, Vol.28 (10), p.2049-2059

2014

Link zum Volltext

Verfügbarkeit prüfen

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Leukemia, 2013-12, Vol.27 (12), p.2311-2321

2013

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

Leukemia, 2017-02, Vol.31 (2), p.340-349

2017

Link zum Volltext

Verfügbarkeit prüfen

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

Leukemia, 2013-08, Vol.27 (8), p.1769-1773

2013

Link zum Volltext

Verfügbarkeit prüfen

P1303: POTENTIATING ANTI‐CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS

HemaSphere, 2022-06, Vol.6 (Suppl), p.1188-1189

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Leukemia, 2013-09, Vol.27 (9), p.1920-1923

2013

Link zum Volltext

Verfügbarkeit prüfen

Chronic Lymphocytic Leukemia: Moving Forward—Rapidly

Seminars in hematology, 2014-07, Vol.51 (3), p.157-157

2014

Link zum Volltext

Verfügbarkeit prüfen

Defective STAT signaling by the leptin receptor in diabetic mice

Proceedings of the National Academy of Sciences - PNAS, 1996-06, Vol.93 (13), p.6231-6235

1996

Link zum Volltext

Verfügbarkeit prüfen

P649: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS ORAL BTK DEGRADER WITH IMID‐LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B‐CELL MALIGNANCIES

HemaSphere, 2022-06, Vol.6, p.547-548

2022

Link zum Volltext

Verfügbarkeit prüfen

ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON‐HODGKIN LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.46-47

2017

Link zum Volltext

Verfügbarkeit prüfen

Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets

Blood, 1996-01, Vol.87 (2), p.567-573

1996

Link zum Volltext

Verfügbarkeit prüfen

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

Haemophilia : the official journal of the World Federation of Hemophilia, 2005-01, Vol.11 (1), p.13-19

2005

Link zum Volltext

Verfügbarkeit prüfen

INSIDE‐OUT VLA‐4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE

Hematological oncology, 2017-06, Vol.35 (S2), p.109-110

2017

Link zum Volltext

Verfügbarkeit prüfen

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2015-12, Vol.100 (12), p.1571-1578

2015

Link zum Volltext

Verfügbarkeit prüfen

A Gene Expression-Based Method to Diagnose Clinically Distinct Subgroups of Diffuse Large B Cell Lymphoma

Proceedings of the National Academy of Sciences - PNAS, 2003-08, Vol.100 (17), p.9991-9996

2003

Link zum Volltext

Verfügbarkeit prüfen

Genetically identical twin transplantation for chronic lymphocytic leukemia

Leukemia, 2007-12, Vol.21 (12), p.2452-2455

2007

Link zum Volltext

Verfügbarkeit prüfen

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL

Hematological oncology, 2023-06, Vol.41 (S2), p.570-571

2023

Link zum Volltext

Verfügbarkeit prüfen

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2016-06, Vol.101 (6), p.e254-e258

2016

Link zum Volltext

Verfügbarkeit prüfen

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

The Lancet (British edition), 2004-01, Vol.363 (9403), p.105-111

2004

Link zum Volltext

Verfügbarkeit prüfen

Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner

Blood, 2005-03, Vol.105 (6), p.2473-2479

2005

Link zum Volltext

Verfügbarkeit prüfen

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Haematologica (Roma), 2016-03, Vol.101 (3), p.e124-e125

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 454

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(425)
Mit Volltextzugriff
(413)

Publikationsform

Sprache

Englisch
(451)
Japanisch
(37)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(225)
Life Sciences & Biomedicine
(213)
Humans
(173)
Hematology
(100)
Female
(77)
Oncology
(76)
Animals
(75)
Male
(75)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(73)
Aged
(54)
Middle Aged
(50)
Biological And Medical Sciences
(41)
Chronic Lymphocytic Leukemia
(40)
Medical Sciences
(40)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(36)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(35)
Adult
(33)
Hematologic And Hematopoietic Diseases
(33)
Veterinary Sciences
(33)
Leukemia
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(160)
Clinical Cancer Research
(23)
Leukemia & Lymphoma
(20)
Cancer Research
(16)
Haematologica
(15)
British Journal Of Haematology
(13)
Equine Veterinary Journal
(13)
The Journal Of Immunology
(12)
Clinical Lymphoma, Myeloma And Leukemia
(10)
Leukemia
(10)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

P1303: POTENTIATING ANTI‐CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Chronic Lymphocytic Leukemia: Moving Forward—Rapidly

Defective STAT signaling by the leptin receptor in diabetic mice

P649: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS ORAL BTK DEGRADER WITH IMID‐LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B‐CELL MALIGNANCIES

ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON‐HODGKIN LYMPHOMA

Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

INSIDE‐OUT VLA‐4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

A Gene Expression-Based Method to Diagnose Clinically Distinct Subgroups of Diffuse Large B Cell Lymphoma

Genetically identical twin transplantation for chronic lymphocytic leukemia

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Suchergebnisse filtern